Detect Type 1 Diabetes Before Clinical Disease Begins.
Beta Intercept™ T1D is a molecular liquid biopsy designed to identify active pancreatic beta-cell injury before irreversible loss of function occurs. Powered by the Intercept IQ™ Molecular Intelligence Platform — combining molecular biology, cell-free DNA, epigenetics, clinical biomarkers, artificial intelligence, and longitudinal data.
- Beta-cell-derived cfDNA
- Methylation-specific signal
- Autoantibody integration
- AI-driven interpretation
Diagnosis today arrives after the biology has already failed.
Type 1 Diabetes is diagnosed after most beta cells are lost. Beta Intercept™ is designed to detect active biological changes years earlier — while intervention is still possible.
Detectable seroconversion to GAD65, IA-2, ZnT8, IAA.
What Beta Intercept™ Measures.
A single blood draw delivers a molecular, biochemical, and immunological profile — unified by Intercept IQ™ into one interpretable disease signal.
Quantitative beta-cell-derived cell-free DNA. Measures active beta-cell apoptosis in real time — the earliest molecular signal of T1D biology.
Average glycemic exposure over ~90 days.
Endogenous insulin production — surrogate for residual beta-cell reserve.
Current circulating insulin — real-time functional readout.
Autoantibodies identify autoimmune activity. BetaDx™ measures beta-cell injury. Together they resolve the complete picture of disease biology.
Powered by the Intercept IQ™ Molecular Intelligence Platform.
Fourteen tightly instrumented stages — from a single blood draw to a physician-facing report and a continuously learning intelligence layer.
Single 6 mL draw at any CLIA collection site.
Proprietary low-input isolation preserves fragmentomic detail.
Cleanroom extraction protocol optimized for picogram inputs.
Bisulfite conversion resolves beta-cell-specific methylation.
Absolute quantitation of tissue-specific cfDNA copies.
High-coverage whole-genome methylation sequencing.
HbA1c, C-Peptide, insulin, autoantibodies integrated.
Reproducible, HIPAA-compliant, containerized pipelines.
Multi-task InterceptIQ models jointly infer disease state.
Federated learning across multi-institutional cohorts.
MD-signed report with molecular narrative.
HL7/FHIR delivery into the EHR.
Every result feeds a de-identified evidence corpus.
Models improve with every outcome and validation study.
Every biological system, one unified molecular profile.
Beta Intercept™ integrates orthogonal biological modalities. Each layer contributes independent evidence; Intercept IQ™ resolves them into a single disease signal.
The molecular narrative — cell by cell.
Hover any stage to reveal the biological state, the BetaDx™ signal, and the residual functional capacity of the islet.
Cytokine-driven insulitis begins.
Twelve data sources. One learning system.
Intercept IQ™ improves with every result — models retrain as new molecular data, outcomes, and evidence enter the system.
The biology begins two decades before the diagnosis.
Beta Intercept™ operates in the pre-clinical window — where measurable molecular events precede autoantibody seroconversion and glycemic dysregulation.
- Years −2001Genetic susceptibilityHLA class II & polygenic risk established at birth.
- Years −1002Loss of immune toleranceRegulatory T-cell dysfunction; autoreactive clones emerge.
- Years −703Beta-cell stressER & mitochondrial stress alter proteostasis.
- Years −504InflammationInsulitis initiated by CD8+ T-cell infiltration.
- Years −305Progressive apoptosisBeta cells die at accelerating rates.
- Years −306cfDNA releaseBeta-cell-specific methylated cfDNA rises — BetaDx™ signal.
- Years −207Autoantibody developmentGAD65, IA-2, ZnT8, IAA seroconversion detectable.
- Year −108Declining insulinFirst-phase insulin response falls; C-peptide drops.
- Year 009Clinical progressionHyperglycemia crosses diagnostic thresholds.
Deployable across the T1D clinical continuum.
Analytical performance — audited, reproducible, published.
Every assay parameter is validated to CLIA / CAP standards and re-verified with each reagent lot and platform release.
A collaborative research network across the T1D community.
Active studies with academic medical centers, natural history cohorts, and clinical trial groups. Selected collaborations shown.
A molecular endpoint for the next generation of T1D therapeutics.
Beta Intercept™ integrates into pharmaceutical programs from discovery through post-market surveillance.
A physician-facing report designed for clinical decisions.
Every result is interpreted, contextualized, and delivered via HL7 / FHIR into the existing electronic health record.
The patient demonstrates a rising beta-cell cfDNA signal in the setting of two positive islet autoantibodies. Findings are consistent with active pre-symptomatic Type 1 Diabetes (Stage 2). Consider referral for immunomodulatory therapy eligibility and enrollment in longitudinal monitoring.
A published, peer-reviewed evidence base.
Browse the full libraryThe first clinical application of the Intercept IQ™ Platform.
Beta Intercept™ T1D is the beginning. The same platform architecture extends across metabolic, oncologic, and neurodegenerative disease.
- 01Beta Intercept™ T1DCommercial
- 02Beta Intercept™ T2DLate-stage
- 03PrediabetesDevelopment
- 04ObesityDevelopment
- 05Metabolic DiseaseResearch
- 06Pancreatic CancerResearch
- 07Neurodegenerative DiseaseResearch
- 08Autoimmune DiseaseResearch
Bring Beta Intercept™ into your clinic, program, or study.
Our scientific affairs team partners with clinicians, researchers, and pharmaceutical development groups to deploy Beta Intercept™ across the T1D continuum.